Rheumatoid Psoriasis Biologic Cost Calculator

Rheumatoid Psoriasis Biologic Cost Calculator helps estimate Korea-related chronic treatment, biologic drug, dialysis, obesity medication, and long-term management assumptions in English.

Rheumatoid and psoriasis biologic cost calculator

Uses the Korean biologic drug model for rheumatoid arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis, biologic or JAK drug choice, biosimilar factor, special-case 10 percent copay, copay ceiling, indemnity, and tax credit.

Korean source inputs

Final after insurance and tax

₩148,000

Final biologic treatment-window estimate

Patient payment before offsets

N/A

NHI copay, non-covered items, room, and selected add-ons before private reimbursement and tax credit.

Estimated private reimbursement

₩592,000

Uses the Korean source generation rules.

Estimated tax credit

₩0

Medical expense credit follows the Korean 3 percent salary threshold and 15 percent credit model.

Cost range

₩133,200 - ₩170,200

Low and high estimate from the source model.

Applied NHI copay

10%

Before private indemnity reimbursement.

Non-covered total

N/A

Self-pay items outside ordinary covered medical benefit.

Annual drug price

₩7,400,000

휴미라 (아달리무맙)

Ceiling refund

₩0

Korean annual copay ceiling applied to covered self-pay.

Biosimilar first-year savings

₩103,600

Biosimilar exists in the source model.

The English calculator calls the same Korean pure function as the Korean page; labels are translated, not re-modeled.

Related calculators

Rheumatoid and psoriasis biologic cost calculator

This page translates the Korean biologic and targeted immune drug guide for rheumatoid arthritis, severe psoriasis, psoriatic arthritis, ankylosing spondylitis, biologic drug presets, JAK inhibitors, biosimilars, special-case registration, copay ceiling, indemnity, and tax credit.

Drug price model

The Korean source models annual drug cost by product. Humira is modeled at KRW 7,400,000 per year, Enbrel at KRW 7,900,000, Remicade at KRW 5,500,000, Simponi at KRW 9,800,000, Actemra at KRW 9,000,000, Orencia at KRW 11,000,000, Rinvoq at KRW 6,700,000, and Cosentyx at KRW 16,000,000.

Biosimilar factors are preserved where the source defines them. For example, Humira biosimilar cost is modeled with a 0.86 factor, Enbrel and Remicade with 0.90, and Stelara with 0.71.

Special-case and ceiling rules

The severe intractable disease special-case rate is 10 percent in this biologic model. For rheumatoid arthritis, seropositive status controls eligibility; psoriasis, psoriatic arthritis, and ankylosing spondylitis are handled under their own special-case eligibility assumptions.

The copay ceiling table is applied by income decile, and the source keeps a KRW 50,000,000 annual private indemnity limit assumption. Medical expense tax credit uses the 3 percent salary threshold and 15 percent credit rate, with a KRW 7,000,000 ordinary medical expense cap unless the severe-disease no-cap rule applies.

What can change the estimate

Drug route, hospital setting, pharmacy dispensing, treatment months, benefit eligibility, special-case registration, biosimilar availability, and income decile can all move the patient burden more than a simple percentage of list price.

The result should be checked against the rheumatology or dermatology prescription, Korean reimbursement criteria, copay ceiling notice, and insurer documentation requirements.